


S3 box | **Non-covalent assemblies of macrocycles.**

Examining structures of the biologically active species of macrocyclic drugs reveals a striking feature: these compounds frequently act as non-covalent assemblies of drug monomers, or as multimeric complexes of drug with endogenous biomolecules. The structures below highlight this feature; functionality that mediates active complex assembly is highlighted in the two-dimensional structures (green and grey regions).



The image of amphotericin B active assembly model is reprinted from reference 1. Structural data has been taken from published sources for the vancomycin dimer², rapamycin³, and rifampicin⁴.

1. Matsumori, N., Yamaji, N., Matsuoka, S., Oishi, T. & Murata, M. Amphotericin B covalent dimers forming sterol-dependent ion-permeable membrane channels. *J. Am. Chem. Soc.* **124**, 4180–4181 (2002).
2. Loll, P. J., Bevivino, A. E., Kerty, B. D. & Axelsen, P. H. Simultaneous recognition of a carboxylate-containing ligand and an intramolecular surrogate ligand in the crystal structure of an asymmetric vancomycin dimer. *J. Am. Chem. Soc.* **119**, 1516–1522 (1997).
3. Choi, J., Chen, J., Schreiber, S. L. & Clardy, J. Structure of the FKBP12–rapamycin complex interacting with the binding domain of human FRAP. *Science* **273**, 239–242 (1996).
4. Artsimovitch, I. *et al.* Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcriptional control by rifamycins. *Cell* **122**, 351–363 (2005).